GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease affecting almost 30% of the world population. Approximately 25% of people with NAFLD develop nonalcoholic steatohepatitis (NASH), the fulminant version of the disease. Diabetes mellitus is present in 22.5% of people with NAFLD and 44.60% of individuals with NASH. This review was undertaken to examine the current contribution of glucagon-like peptide 1 (GLP-1) receptor agonists to the pharmacotherapy of diabetic nonalcoholic steatohepatitis. Areas covered: The author analyzed the current status of GLP-1 receptor agonists for pharmacotherapy of diabetic NASH. Research data and literature reports were taken from the database and or websites of Diabetes UK, American Diabetes Association, ClinicalTrials.gov, PubMed, and Scopus. The keywords utilized included type 2 diabetes, GLP-1, NASH, NAFLD, and clinical trials. Expert opinion: Since diabetic NASH is associated with obesity, diabetes mellitus, oxidative stress and inflammation, drugs capable of mitigating all of these conditions simultaneously, are most ideal for the treatment of diabetic NASH. These drugs include (in order of relevance), GLP-1 receptor agonists, GLP-1 and GIP dual receptor agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and pioglitazone. The future, FDA-approved drug for diabetic NASH treatment will likely be GLP-1 agonist, which could be used as monotherapy or in combination with other drugs.

Original languageEnglish
Pages (from-to)223-232
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume25
Issue number3
DOIs
Publication statusPublished - 2024

Keywords

  • GLP-1 and GIP dual receptor agonists
  • GLP-1 receptor agonists
  • PNPLA3 gene
  • diabetes mellitus
  • dyslipidemia
  • insulin resistance
  • nonalcoholic steatohepatitis
  • obesity
  • pharmacotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients'. Together they form a unique fingerprint.

Cite this